Monitorins of vancomycin plasma levels in patients undergoing hemodialysis;Monitorización de las concentraciones plasmáticas de vancomicina en pacientes en hemodiálisis

Farmacia Hospitalaria

Volumn 29, Issue 6, 2005, Pages 354-358

  Ruano, Rosalía ^a,b   Martin Reyes G ^a   Munoz I ^a   Pizarro, J L ^a   Gallego, C ^a   Moreno, M V ^a   Ruiz, J ^a   Franquelo, R ^a   Ramos, B ^a   Fernandez J ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b NONE   (Spain)

Author keywords

Hemodialysis; Low ultrafiltration and high ultrafiltration; Plasma levels; Vancomycin

Indexed keywords

VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; IMMUNOASSAY; MALE; PATIENT MONITORING; TITRIMETRY; ULTRAFILTRATION;

EID: 32244444996     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-6343(05)73695-3     Document Type: Article

References (22)

1. a ed. Pamplona: Masson, 1997. p. 1116-9.
2. Kessler M, Hoen B, Mayeux D, Hestin D, Fonenaille C. Bacteremia in patients on chronic hemodialysis. A multicenter prospective survey. Nephron 1993; 64: 95-100.
3. Walters BAJ, Molini M, Rosenthal A, DiDominie V, Bander S. Incidence of bacteremia in hemodialysis patients. J Am Soc Nephrol 1995; 567.
4. Barth RH, DeVincenzo N. Bacteremia in hospital-based, high-flux hemodialysis (HD): bacteriology, antibiotic susceptibilities and relation to vascular access. J Am Soc Nephrol 1994; 432.
5. Drugdex® Editorial Staff. Drugdex® Information System. Micromedex INC. Englewood, Colorado (2003). Drug evaluation monographs of vancomicyn. (Consulta Octubre 2004). http://www.sefh.es/micromedex.htm.
6. Launay-Vacher V, Izzedine H, Mercadal L, Deray G. Clinical review: use of vancomicyn in haemodialysis patients. Critical Care 2002; 6: 313-6.
7. a ed. Barcelona: Masson, 2003. p. 148-9.
8. Schwab S, Sexton D. Management of infected cuffed central venous catheters used for hemodialysis. Up To Date. 2004. (http://uptodate.com) (Consulta Noviembre 2004).
9. Moellering RC, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981; 94: 343-6.
10. Operaciones del Sistema Axsym®. Abbott, División Diagnósticos. 1996.
11. Scott M, William LM, Kraus MA, Clark WR, Carfagna MA, Mueller BA. Effects of dialysis membrane on intradialytic vancomycin administration. Pharmacotherapy 1997; 17: 256-62.
12. Scott MK, Mueller BA, Clark WR. Vancomycin mass transfer characteristics of high-flux cellulosic dialysers. Nephrol Dial Transplant 1997; 12: 2647-53.
13. Hudson JQ, Comstock TJ, Feldman GM. Evaluation of an in vitro dialysis system to predict drug removal. Nephrol Dial Transplant 2004; 19: 400-5.
14. Foote EF, Dreitlein WB, Steward CA, Kapoian T, Walker JA, Sherman RA. Pharmacokinetics of vancomycin when administered during high flux hemodialysis. Clin Nephrol 1998; 50: 51-5.
15. Pollard TA, Lampasona V, Akkerman S, Tom K, Hooks MA, Mullina M, et al. Vancomicyn redistribution: doping recommendations following high-flux hemodialysis. Kidney Int 1994; 45: 232-7.
16. Torras J, Cao C, Rivas MC, Cano M, Fernández E, Montoliu J. Pharmacokinetics of vancomycin in patients undergoing hemodialysis with polyacrylonitrile. Clin Nephrol 1991; 36: 35-41.
17. Lanese DM, Alfrey PS, Molitoris BA. Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers. Kidney Int 1989; 35: 1409-12.
18. DeSoi CA, Sahm DF, Umans JG. Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes. Am J Kidney Dis 1992; 20: 354-60.
19. Stamatakis MK, Schreiber JM, Slain D, Gunel E. Vancomycin administration during dialysis with low-flux polysulfone membranes: traditional versus a supplemental dosage regimen. Am J Health Syst Pharm 2003; 60: 1564-8.
20. Barth RH, DeVincenzo N. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Kidney Int 1996; 50: 929-36.
21. Zoer J, Schrander-van der Meer AM, van Dorp WT. Dosage recommendations of vancomicyn during haemodialysis with highly permeable membranes. Pharm World Sci 1997; 19: 191-6.
22. Touchette MA, Patel RV, Anandan JV, Dumler F, Zarowitz BJ. Vancomycin removal by high-flux polysulfone hemodialysis membranes in critically ill patients with end-stage renal disease. Am J Kidney Dis 1995; 26: 469-74.